Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation.

Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS.

Postgrad Med J. 1973 Mar;49(569):152-8. No abstract available.

2.

Age-related response to 1000 CCA unit zonally purified, inactivated influenza vaccines in volunteers in the U.S.A.

Marine WM, Thomas JE.

Postgrad Med J. 1973 Mar;49(569):164-8. No abstract available.

3.

Influenza vaccines purified by zonal ultracentrifugation.

Filczak K, Semkow R, Wrzos H, Zakrzewski K, Zgorzelska K.

Acta Microbiol Pol A. 1973;5(3):261-70. No abstract available.

PMID:
4769561
4.

Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses.

Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS.

Bull World Health Organ. 1969;41(3):525-30.

5.

A new subunit influenza vaccine; acceptability compared with standard vaccines and antigenicity in increasing dosage.

Ruben FL, Jackson GG.

Postgrad Med J. 1973 Mar;49(569):185-92. No abstract available.

6.

A clinical and serologic comparison of standard and purified bivalent inactivated influenza vaccines.

Finklea JF, Sandifer SH, Peck FB, Manos JP.

J Infect Dis. 1969 Dec;120(6):708-12. No abstract available.

PMID:
4911903
7.

Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man.

Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS, Hierholzer JC.

Am J Epidemiol. 1970 Oct;92(4):248-56. No abstract available.

PMID:
5458217
8.

A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.

Brady MI, Furminger IG.

J Hyg (Lond). 1976 Oct;77(2):173-80.

9.

Antigenicity of influenza vaccine from bovine cell cultures.

Leiderman E, Mogabgab WJ.

Appl Microbiol. 1969 Oct;18(4):596-600.

10.

Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization.

Phillips CA, Forsyth BR, Christmas WA, Gump DW, Whorton EB, Rogers I, Rudin A.

J Infect Dis. 1970 Jul-Aug;122(1):26-32. No abstract available.

PMID:
5433710
11.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

PMID:
19281330
12.

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF.

J Infect Dis. 1994 Jan;169(1):68-76.

PMID:
8277200
13.

Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience.

Neuzil KM, Dupont WD, Wright PF, Edwards KM.

Pediatr Infect Dis J. 2001 Aug;20(8):733-40.

PMID:
11734733
14.

Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.

Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.

J Infect Dis. 2006 Oct 15;194(8):1032-9. Epub 2006 Sep 11.

PMID:
16991077
15.

A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.

Samdal HH, Bakke H, Oftung F, Holst J, Haugen IL, Korsvold GE, Kristoffersen AC, Krogh G, Nord K, Rappuoli R, Berstad AK, Haneberg B.

Hum Vaccin. 2005 Mar-Apr;1(2):85-90. Epub 2005 Mar 16.

PMID:
17038826
17.

Inactivated influenza virus vaccines in man: a comparative study of subunit and split vaccines using two methods for assessment of antibody responses.

Jennings R, Smith TL, Spencer RC, Mellersh AM, Edey D, Fenton P, Potter CW.

Vaccine. 1984 Mar;2(1):75-80.

PMID:
6531953
18.

[Antibody response to anti-influenza vaccination with vaccine purified by differential ultracentrifugation and with vaccine purified by zonal ultracentrifugation].

Verde F, Frezza G, Russo V, Visconti M.

Boll Soc Ital Biol Sper. 1973 Feb 28;49(4):178-81. Italian. No abstract available.

PMID:
4779761
19.

[An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].

Lupulescu E, Ioniţă E, Botez D, Matepciuc M, Tabra ME, Tecu C, Alexandrescu V, Munţiu A.

Bacteriol Virusol Parazitol Epidemiol. 1997 Jan-Jun;42(1-2):110-2. Romanian. No abstract available.

PMID:
9235136
20.

Immunogenicity of inactivated influenza virus vaccine in chronic renal failure.

Jordan MC, Rousseau WE, Tegtmeier GE, Noble GR, Muth RG, Chin TD.

Ann Intern Med. 1973 Dec;79(6):790-4. No abstract available.

PMID:
4761907

Supplemental Content

Support Center